Quince Therapeutics appoints Brigette Roberts CEO in management overhaul

PUBT · 1d ago
Quince Therapeutics appoints Brigette Roberts CEO in management overhaul
  • Quince Therapeutics named Brigette Roberts as CEO; she previously led Orphai Therapeutics and served on Quince’s board.
  • John Militello was appointed CFO; he previously ran finance at Quince and held senior finance roles at Rocket Pharmaceuticals.
  • Keith R. Fandrick was named COO; he previously led technical operations at Quince and served as COO of Orphai.
  • Dirk Thye resigned as CEO and CMO; Brendan Hannah resigned as COO, CBO, and chief compliance officer.
  • Board added Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise; backgrounds span respiratory drug development, biotech finance, FDA strategy, commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-418538), on October 09, 2026, and is solely responsible for the information contained therein.